Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
IMMU's Cash to Debt is ranked higher than
89% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. IMMU: No Debt )
IMMU' s 10-Year Cash to Debt Range
Min: 0.33   Max: No Debt
Current: No Debt

Equity to Asset 0.72
IMMU's Equity to Asset is ranked higher than
76% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. IMMU: 0.72 )
IMMU' s 10-Year Equity to Asset Range
Min: -0.58   Max: 0.92
Current: 0.72

-0.58
0.92
Interest Coverage No Debt
IMMU's Interest Coverage is ranked higher than
70% of the 577 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. IMMU: No Debt )
IMMU' s 10-Year Interest Coverage Range
Min: 354.57   Max: 9999.99
Current: No Debt

354.57
9999.99
F-Score: 2
Z-Score: 10.59
M-Score: -3.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -920.22
IMMU's Operating margin (%) is ranked higher than
58% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. IMMU: -920.22 )
IMMU' s 10-Year Operating margin (%) Range
Min: -782.35   Max: 55.69
Current: -920.22

-782.35
55.69
Net-margin (%) -916.86
IMMU's Net-margin (%) is ranked higher than
58% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. IMMU: -916.86 )
IMMU' s 10-Year Net-margin (%) Range
Min: -782.35   Max: 60.72
Current: -916.86

-782.35
60.72
ROE (%) -139.23
IMMU's ROE (%) is ranked higher than
56% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. IMMU: -139.23 )
IMMU' s 10-Year ROE (%) Range
Min: -1147.9   Max: 740.72
Current: -139.23

-1147.9
740.72
ROA (%) -114.42
IMMU's ROA (%) is ranked higher than
53% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. IMMU: -114.42 )
IMMU' s 10-Year ROA (%) Range
Min: -74.76   Max: 74.44
Current: -114.42

-74.76
74.44
ROC (Joel Greenblatt) (%) -2076.88
IMMU's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. IMMU: -2076.88 )
IMMU' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1787.04   Max: 721.44
Current: -2076.88

-1787.04
721.44
Revenue Growth (%) -18.10
IMMU's Revenue Growth (%) is ranked higher than
68% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. IMMU: -18.10 )
IMMU' s 10-Year Revenue Growth (%) Range
Min: -57.8   Max: 83.3
Current: -18.1

-57.8
83.3
EBITDA Growth (%) 21.30
IMMU's EBITDA Growth (%) is ranked higher than
91% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. IMMU: 21.30 )
IMMU' s 10-Year EBITDA Growth (%) Range
Min: -25.5   Max: 54.2
Current: 21.3

-25.5
54.2
EPS Growth (%) 28.10
IMMU's EPS Growth (%) is ranked higher than
92% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. IMMU: 28.10 )
IMMU' s 10-Year EPS Growth (%) Range
Min: -36.3   Max: 84.2
Current: 28.1

-36.3
84.2
» IMMU's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

IMMU Guru Trades in

Q3 2013

IMMU Guru Trades in Q3 2013

Steven Cohen 1,810,000 sh (New)
Jim Simons 260,207 sh (New)
» More
Q4 2013

IMMU Guru Trades in Q4 2013

Paul Tudor Jones 18,678 sh (New)
Jim Simons Sold Out
Steven Cohen 1,398,548 sh (-22.73%)
» More
Q1 2014

IMMU Guru Trades in Q1 2014

Steven Cohen Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with IMMU

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 14.80
IMMU's P/B is ranked higher than
61% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. IMMU: 14.80 )
IMMU' s 10-Year P/B Range
Min: 4.32   Max: 249
Current: 14.8

4.32
249
P/S 81.60
IMMU's P/S is ranked higher than
68% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. IMMU: 81.60 )
IMMU' s 10-Year P/S Range
Min: 2.97   Max: 114.5
Current: 81.6

2.97
114.5
EV-to-EBIT -8.99
IMMU's EV-to-EBIT is ranked higher than
71% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. IMMU: -8.99 )
IMMU' s 10-Year EV-to-EBIT Range
Min: -343.7   Max: 175.3
Current: -8.99

-343.7
175.3
Current Ratio 3.71
IMMU's Current Ratio is ranked higher than
69% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. IMMU: 3.71 )
IMMU' s 10-Year Current Ratio Range
Min: 0.6   Max: 12.5
Current: 3.71

0.6
12.5
Quick Ratio 3.63
IMMU's Quick Ratio is ranked higher than
69% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. IMMU: 3.63 )
IMMU' s 10-Year Quick Ratio Range
Min: 0.59   Max: 12.23
Current: 3.63

0.59
12.23

Valuation & Return

vs
industry
vs
history
Price/Net Cash 19.35
IMMU's Price/Net Cash is ranked higher than
77% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. IMMU: 19.35 )
IMMU' s 10-Year Price/Net Cash Range
Min: 5.36   Max: 218.75
Current: 19.35

5.36
218.75
Price/Net Current Asset Value 18.54
IMMU's Price/Net Current Asset Value is ranked higher than
76% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. IMMU: 18.54 )
IMMU' s 10-Year Price/Net Current Asset Value Range
Min: 5.24   Max: 462.5
Current: 18.54

5.24
462.5
Price/Tangible Book 15.34
IMMU's Price/Tangible Book is ranked higher than
66% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. IMMU: 15.34 )
IMMU' s 10-Year Price/Tangible Book Range
Min: 3.08   Max: 96
Current: 15.34

3.08
96
Price/Median PS Value 4.04
IMMU's Price/Median PS Value is ranked higher than
70% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. IMMU: 4.04 )
IMMU' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 7.4
Current: 4.04

0.12
7.4
Earnings Yield (Greenblatt) -11.50
IMMU's Earnings Yield (Greenblatt) is ranked higher than
67% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. IMMU: -11.50 )
IMMU' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 17.4
Current: -11.5

0.6
17.4

Analyst Estimate

Jun15
Revenue(Mil) 4
EPS($) -0.56
EPS without NRI($) -0.56

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:IM3.Germany,
Immunomedics Inc was incorporated in Delaware in 1982. It is a biopharmaceutical company which develops monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. It has developed advanced proprietary technologies that allow it to create humanized antibodies that can be used either alone in unlabeled or 'naked' form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create targeted agents. Using these technologies, it has built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. Its product candidate, epratuzumab, is currently in two Phase III clinical trials in lupus. In oncology, the Company is planning to launch a Phase III pivotal trial for clivatuzumab labeled with a radioisotope in pancreatic cancer patients. Other solid tumor therapeutics in Phase II clinical development includes 2 antibody-drug conjugates; labetuzumab-SN-38 (IMMU-130) and hRS7-SN-38 (IMMU-132).It also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a DOCK-AND-LOCK (DNL) method with for making fusion proteins and multifunctional antibodies. DNL is being used particularly to make bispecific antibodies targeting cancers and infectious diseases as a T-cell redirecting immunotherapy, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies. It has licensed its product candidate, epratuzumab, to UCB S.A., or UCB, for the treatment of all non-cancer indications worldwide. Epratuzumab's advanced clinical testing is for the treatment of systemic lupus erythematosus, or SLE (lupus), in non-Hodgkin lymphoma, or NHL and acute lymphoblastic leukemia, or ALL. During the 2013 fiscal year, it have completed a Phase Ib clinical trial evaluating clivatuzumab tetraxetan (hPAM4) labeled with yttrium-90, or Y-90, with and without low-dose gemcitabine, in pancreatic cancer patients who had received at least 2 prior therapies. It also initiated a randomized Phase Ib study examining the Y-90-labeled clivatuzumab tetraxetan, with and without low-dose gemcitabine, in pancreatic cancer patients who have received at least 2 prior therapies. It is also conducting a National Cancer Institute, or NCI, grant-supported study combining unlabeled veltuzumab with Y-90-labeled epratuzumab tetraxetan in patients with diffuse large B-cell lymphoma, or DLBCL, the aggressive form of NHL. The second ADC in its product pipeline is, labetuzumab-SN-38, which is in a Phase I/II trial in patients with advanced colorectal cancer. In the first half of fiscal 2013, it plan to begin a new study examining the safety and tolerability of its third ADC, hRS7-SN-38, in patients with solid cancers, for which an Investigational New Drug (IND) application has been filed with the Food and Drug Administration (FDA). The Company competes with Biogen Idec, Roche, GlaxoSmithKline, Seattle Genetics, Merck Serono,
» More Articles for IMMU

Headlines

Articles On GuruFocus.com
Immunomedics Inc. Reports Operating Results (10-Q) Feb 04 2011 
Immunomedics Inc. Reports Operating Results (10-Q) Nov 04 2010 
Immunomedics Inc. Reports Operating Results (10-K) Aug 26 2010 
Fastest Growing Magic Formula Stocks: Jiangbo Pharmaceuticals, DragonWave, Immunomedics, Genoptix, P Jul 15 2010 
Immunomedics Inc. Reports Operating Results (10-Q) May 10 2010 
Immunomedics Inc. Reports Operating Results (10-Q) Feb 02 2010 
Immunomedics Inc. Reports Operating Results (10-Q) Nov 06 2009 
Immunomedics Inc. Reports Operating Results (10-K) Aug 27 2009 
Immunomedics Inc. Reports Operating Results (10-Q) May 11 2009 
Immunomedics Inc. Reports Operating Results (10-Q) Feb 09 2009 

More From Other Websites
IMMUNOMEDICS INC Files SEC form 8-K, Other Events Dec 17 2014
IMMUNOMEDICS REPORTS PRELIMINARY RESULTS FROM PRETARGETED IMAGING STUDY IN PATIENTS WITH METASTATIC... Dec 15 2014
Immunomedics Reports Preliminary Results From Pretargeted Imaging Study in Patients With Metastatic... Dec 15 2014
IMMUNOMEDICS REPORTS EXPANDED PHASE 1/2 TRIALS CONFIRM ACTIVITY AND GOOD SAFETY PROFILE OF... Dec 12 2014
Immunomedics Reports Expanded Phase 1/2 Trials Confirm Activity and Good Safety Profile of... Dec 12 2014
IMMUNOMEDICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Financial... Dec 04 2014
IMMUNOMEDICS TO PRESENT AT 25TH ANNUAL OPPENHEIMER HEALTHCARE CONFERENCE Dec 04 2014
Immunomedics to Present at 25th Annual Oppenheimer Healthcare Conference Dec 04 2014
IMMUNOMEDICS ANNOUNCES OUTCOME OF 2014 ANNUAL MEETING OF STOCKHOLDERS Dec 03 2014
Immunomedics Announces Outcome of 2014 Annual Meeting of Stockholders Dec 03 2014
Immunomedics' Veltuzumab Receives Orphan Drug Status Nov 24 2014
IMMUNOMEDICS ANNOUNCES ORPHAN DRUG DESIGNATION FOR VELTUZUMAB FOR THE TREATMENT OF PEMPHIGUS Nov 21 2014
Immunomedics Announces Orphan Drug Designation for Veltuzumab for the Treatment of Pemphigus Nov 21 2014
IMMUNOMEDICS PRESENTS CLINICAL DATA ON NOVEL ANTIBODY-DRUG CONJUGATES FOR SOLID CANCER THERAPY Nov 20 2014
Immunomedics Presents Clinical Data on Novel Antibody-Drug Conjugates for Solid Cancer Therapy Nov 20 2014
IMMUNOMEDICS INC Financials Nov 14 2014
Immunomedics Announces Six Presentations on Epratuzumab in Lupus at Leading Rheumatology Meeting Nov 14 2014
10-Q for Immunomedics, Inc. Nov 07 2014
Immunomedics Receives Third Edison Patent Award From Research & Development Council of New Jersey Nov 07 2014
Immunomedics (IMMU) Weak On High Volume Nov 06 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK